The respiratory drugs market refers to the segment of the pharmaceutical industry that deals with drugs designed to treat respiratory disorders, including asthma, chronic obstructive pulmonary disease ...

Scientists have made a key breakthrough in treating respiratory diseases by developing a new drug delivery system that ...

We are currently experiencing a renaissance in the treatment landscape for respiratory disease, but we can do better. When I first began my career in drug development more than 20 years ago ...

SAE Media Group's Inaugural Respiratory Drug Delivery will be coming to London in November ... biopharmaceutical considerations for efficient delivery to the respiratory system with key insights from ...

World revenue for the Respiratory Drug Delivery Market is forecast to ... have the same features and objectives, the Quality System 111 Regulation (21 CFR 820) for devices provides design ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...

An IL-5 inhibitor drug, Fasenra competes with GlaxoSmithKline’s Nucala (mepolizumab), which has been approved in Japan since March 2016 and was first to market in the US and EU.

and medications or recreational drugs that impair the function of the central nervous system. If a person suspects respiratory depression, they should seek emergency medical attention.